Stocks Health care ANIX
NASDAQ · Health careAnixa Biosciences Inc (ANIX)
It posted a net loss of $10.4M. At July 31, 2026 it held $1.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 9, 2026.
What Anixa Biosciences Inc does
Anixa Biosciences Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANIX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$10.9M | -$0.34 | n/a |
| 2024 | $210K | -$12.6M | -$0.39 | n/a |
| 2023 | $210K | -$9.8M | -$0.32 | n/a |
| 2022 | n/a | -$13.6M | $0.45 | n/a |
| 2022 | $512K | -$13M | -$0.45 | n/a |
| 2020 | n/a | -$10M | -$0.45 | -$6.2M |
Latest SEC filings
What Anixa Biosciences Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 9, 2026Quarterly report 10-Q · period to July 31, 2026
- June 10, 2026Quarterly report 10-Q · period to April 30, 2026
- March 11, 2026
- March 9, 2026Quarterly report 10-Q · period to January 31, 2026
- February 9, 2026
- January 28, 2026Proxy statement DEF 14A
- January 12, 2026
- January 12, 2026Annual report 10-K · period to October 31, 2025
- January 6, 2026Activist stake changed SCHEDULE 13D/A
- December 12, 2025
Questions about ANIX
What does Anixa Biosciences Inc do?
Anixa Biosciences Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANIX.
Is Anixa Biosciences Inc profitable?
No. Over the twelve months to July 31, 2026 it reported a net loss of $10.4M.
When did Anixa Biosciences Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 9, 2026. It covers the period to July 31, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.
Similar companies
Follow ANIX
Get an email when Anixa Biosciences Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow ANIX: get an email when it filesWhere the numbers come from
Financial figures are the values Anixa Biosciences Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.